MyoKardia, Inc
NEWS
MyoKardia, Inc. was acquired by Bristol Myers Squibb (BMS) in 2020.
Only a year after buying cancer specialist Celgene for $74 billion, Bristol Myers Squibb announced it is buying cardiology company MyoKardia for about $13.1 billion. The deal is expected to close before the end of the year.
Putting your employees and company culture first keeps the focus on inclusion and innovation, giving the company an incredible competitive advantage.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
In Phase III EXPLORER-HCM clinical trial, mavacamten demonstrated a robust treatment effect and met all primary and secondary endpoints.
It was a busy week for clinical trial announcements. Here’s a look.
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
MyoKardia, Inc., announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019, at 4:10 p.m. ET in New York, NY.
Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among HCM Patients Referred for Invasive Procedures
IN THE PRESS